EUCAST Technical note on Amphotericin B  by Lass-Flörl, C. et al.
EUCAST Technical note on
Amphotericin B
C. Lass-Flo¨rl1, M. C. Arendrup2, J.-L. Rodriguez-Tudela3,
M. Cuenca-Estrella3, P. Donnelly4, W. Hope5 and
The European Committee on Antimicrobial Susceptibility
Testing – Subcommittee on Antifungal Susceptibility
Testing (EUCAST-AFST)*
1) Division of Hygiene and Medical Microbiology, Innsbruck
Medical University, Innsbruck, Austria, 2) Unit of Mycology, Department
of Mictobiological Surveillance and Research, Statens Serum Institute,
Copenhagen, Denmark, 3) Mycology Reference Laboratory, National
Center for Microbiology, Instituto de Salud Carlos Ill, Majadahonda, Spain,
4) Department of Haematology, Radboud University Nijmegen Medical
Centre & Nijmegan University Centre for Infectious Diseases Radboud
University, Nijmegen, The Netherlands and 5) The University of
Manchester, Manchester, UK
Abstract
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for amphotericin
B for Candida spp. This Technical Note is based on the
EUCAST amphotericin B rationale document (available on the
EUCAST website: http://www.eucast.org). Species-speciﬁc
breakpoints for C. albicans, C. glabrata, C. krusei, C. parapsilosis
and C. tropicalis are S: MIC £1 mg/L, R: MIC > 1 mg/L. There
are insufﬁcient data to set breakpoints for other species. The
breakpoints are based upon pharmacokinetic data, epidemio-
logical cut-ff values and clinical experience. Breakpoints will be
reviewed regularly.
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Introduction
Amphotericin B is a polyene antifungal agent that is active
against yeasts and moulds. In Europe, it is available in four dif-
ferent parental formulations, including amphotericin B deoxy-
cholate and three lipid formulations. The active compound is
identical but the pharmacokinetics and toxicity proﬁles vary
from formulation to formulation. The licensed indications for
each formulation are as follows: amphotericin B deoxycholate
(AMB-DC), serious infections due to amphotericin B-suscepti-
ble fungi; amphotericin B lipid complex (ABLC), ﬁrst-line
treatment of systemic Candida infections; amphotericin B col-
loidal dispersion (ABCD), serious infections due to amphoter-
icin-susceptible fungi, where amphotericin B deoxycholate
is contraindicated or has failed; liposomal amphotericn B
(L-amphotericin B), treatment of invasive fungal infections due
to amphotericin B-susceptible fungi, and treatment of sus-
pected fungal infection in neutropenic patients with persistent
fever despite antibacterial treatment for 5–7 days.
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints of amphoteri-
cin B for Candida spp. This Technical Note is based on the
EUCAST amphotericin B rationale document (available on
the EUCAST website: http://www.eucast.org). The rationale
document includes more detail and published references




The breakpoints are based upon the following dosages
administered intravenously: amphotericin B, 0.6–1 mg/kg/
day; liposomal amphotericin, 3 mg/kg/day; amphotericin B
lipid complex (ABLC) and amphotericin B colloidal disper-
sion (ABCD), 3–5 mg/kg/day. Breakpoints were established
using MIC values from multiple laboratories. Wild-type
isolates of each of the ﬁve common species (C. albicans,
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C. glabrata, C. krusei, C. parapsilosis and C. tropicalis) exhibit
MICs £ 1 mg/L.
The EUCAST breakpoints (Table 1) are based on pharma-
cokinetic [1–7] and microbiological data and clinical experi-
ence [8–15]. For most studies clinical outcome data were
not speciﬁed for the individual Candida species. Combining
the studies that provided such data [8,12,14], failure rates
were as follows. For L-amphotericin B the overall failure rate
was 9% (16/174) and for individual species: C. albicans 11%
(7/73), C. tropicalis 4% (2/45), C. parapsilosis 10% (3/29),
C. glabrata 20% (3/15) and C. krusei 20% (1/5). For ampho-
tericin B deoxycholate the overall failure rate was 38% (44/
115) and for individual species: C. albicans 8% and C. krusei
3%. These data indicate that the ﬁve commonest species are
good targets for all amphotericin B formulations. There are
too few data to enable any deﬁnitive recommendation to be
made for species other than those addressed in this docu-
ment. None of the clinical studies estimated MICs using
EUCAST methodology so a direct correlation between in vi-
tro MICs and clinical outcome is currently not possible. Fur-
thermore, there is no clinical experience with isolates with
acquired resistance mechanisms; hence the breakpoints are
based upon epidemiological cut-off values.
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C. albicans S £ 1 R > 1
C. glabrata S £ 1 R > 1
C. parapsilosis S £ 1 R > 1
C. tropicalis S £ 1 R > 1
C. krusei S £ 1 R > 1
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